pharmaceutical investing Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
